Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
43 results
  • Melanoma, Lung Cancer, Breast Cancer, Ovarian Cancer, Colorectal Cancer

20-079          Phase I

A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies (View details on

  • Ovarian Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer (View details on

  • Lymphoma, Ovarian Cancer, Leukemia, Metastatic/Advanced Cancer, Sarcoma, Head and Neck Cancer, Breast Cancer

20-035          Phase II

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors (View details on

  • Head and Neck Cancer, Ovarian Cancer, Esophageal Cancer, Cervical Cancer, Breast Cancer, Lung Cancer

22-281          Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors (View details on

  • Colorectal Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer

20-211          Phase I

A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors (View details on

  • Lung Cancer, Endometrial Cancer, Breast Cancer, Colorectal Cancer, Ovarian Cancer

20-444          Phase I

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors (View details on

  • Ovarian Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer

22-235          Phase I

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors (View details on

  • Endometrial Cancer, Lung Cancer, Ovarian Cancer, Uterine Cancer, Melanoma, Bladder Cancer, Breast Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers (View details on

  • Ovarian Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001) (View details on

Showing 1 - 10 of 43 results